The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Abstract
CONTEXT: The alpha7 nicotinic acetylcholine receptor gene, CHRNA7, is associated with genetic transmission of schizophrenia and related cognitive and neurophysiological sensory gating deficits. Cognitive dysfunction is responsible for significant psychosocial disability in schizophrenia. Nicotine, a low-potency agonist at the alpha7 receptor, has some positive effects on neurophysiological and neurocognitive deficits associated with schizophrenia, which suggests that more effective receptor activation might meaningfully enhance cognition in schizophrenia. OBJECTIVES: To determine if 3-[(2,4-dimethoxy)benzylidene]anabaseine (DMXB-A), a natural alkaloid derivative and a partial alpha7 nicotinic cholinergic agonist, significantly improves neurocognition, and to assess, by effects on P50 auditory evoked potential inhibition, whether its neurobiological actions are consistent with activation of alpha7 nicotinic receptors. DESIGN: Randomized, double-blind crossover trial of 2 drug doses and 1 placebo. SETTING: General clinical research center. PATIENTS: Twelve persons with schizophrenia who did not smoke and were concurrently treated with antipsychotic drugs. One person was withdrawn because of a transient decrease in white blood cell count. INTERVENTION: Administration of DMXB-A. MAIN OUTCOME MEASURES: Total scale score of the Repeatable Battery for the Assessment of Neuropsychological Status and P50 inhibitory gating. RESULTS: Significant neurocognitive improvement was found on the Repeatable Battery for the Assessment of Neuropsychological Status total scale score, particularly for the lower DMXB-A dose compared with placebo. Effects were greater than those of nicotine in a similar study. Significant improvement in P50 inhibition also occurred. Patients generally tolerated the drug well. CONCLUSIONS: An alpha7 nicotinic agonist appears to have positive effects on neurocognition in persons with schizophrenia. Longer trials are needed to determine the clinical utility of this novel treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141
Self-citationNormalization of auditory physiology by cigarette smoking in schizophrenic patients
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1856 · Cited by 679
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678
Self-citationBilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
INPUT DYSFUNCTION IN SCHIZOPHRENIA.
Venables, P. H. (1964) · PubMed · Cited by 473
Leonard, S., Gault, J., Hopkins, J., Logel, J., Vianzon, R., Short, M., Drebing, C., Berger, R., Venn, D., Sirota, P., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1085 · Cited by 441
Self-citationFrazier, C. J., Rollins, Y. D., Breese, C. R., Leonard, S., Freedman, R., & Dunwiddie, T. V. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-04-01187.1998 · Cited by 374
Self-citationGold, J. M., Queern, C., Iannone, V. N., & Buchanan, R. W. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1944 · Cited by 325
Selective α 7 -nicotinic agonists normalize inhibition of auditory response in DBA mice
Stevens, K. E., Kem, W. R., Mahnir, V. M., & Freedman, R. (1998) · Psychopharmacology · doi:10.1007/s002130050573 · Cited by 269
Self-citationKaufmann, C. A., Suarez, B., Malaspina, D., Pepple, J., Svrakic, D., Markel, P. D., Meyer, J., Zambuto, C. T., Schmitt, K., Matise, T. C., et al. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980710)81:4<282::aid-ajmg2>3.0.co;2-w · Cited by 267
Cholinergic gating of response to auditory stimuli in rat hippocampus
Luntz-Leybman, V., Bickford, P. C., & Freedman, R. (1992) · Brain Research · doi:10.1016/0006-8993(92)91437-j · Cited by 264
Self-citationCourt, J., Spurden, D., Lloyd, S., McKeith, I., Ballard, C., Cairns, N., Kerwin, R., Perry, R., & Perry, E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731590.x · Cited by 254
Olincy, A., Young, D. A., & Freedman, R. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00302-2 · Cited by 252
Self-citationSmith, R. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00324-x · Cited by 247
Alkondon, M., & Albuquerque, E. X. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.86.6.3043 · Cited by 238
Kitagawa, H., Takenouchi, T., Azuma, R., Wesnes, K. A., Kramer, W. G., Clody, D. E., & Burnett, A. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300028 · Cited by 238
Effects of Nicotine on Cognitive Deficits in Schizophrenia
Harris, J. G., Kongs, S., Allensworth, D., Martin, L., Tregellas, J., Sullivan, B., Zerbe, G., & Freedman, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300450 · Cited by 237
Self-citationNicotine effects on brain function and functional connectivity in schizophrenia
Jacobsen, L. K., D'Souza, D. C., Mencl, W. E., Pugh, K. R., Skudlarski, P., & Krystal, J. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.023 · Cited by 232
Effects of Smoking Abstinence on Visuospatial Working Memory Function in Schizophrenia
George, T. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00296-2 · Cited by 226
Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia
Cullum, C. M., Harris, J. G., Waldo, M. C., Smernoff, E., Madison, A., Nagamoto, H. T., Griffith, J., Adler, L. E., & Freedman, R. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90048-n · Cited by 212
Self-citationVaried Effects of Atypical Neuroleptics on P50 Auditory Gating in Schizophrenia Patients
Adler, L. E., Olincy, A., Cawthra, E. M., McRae, K. A., Harris, J. G., Nagamoto, H. T., Waldo, M. C., Hall, M.-H., Bowles, A., Woodward, L., et al. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1822 · Cited by 197
Self-citationde Fiebre, C. M., Meyer, E. M., Henry, J. C., Muraskin, S. I., Kem, W. R., & Papke, R. L. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08515-3 · Cited by 197
Self-citationEffects of clozapine on smoking in chronic schizophrenic outpatients.
George, T. P., Sernyak, M. J., Ziedonis, D. M., & Woods, S. W. (1995) · PubMed · Cited by 179
Dépatie, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00372-x · Cited by 175
Smoking and therapeutic response to clozapine in patients with schizophrenia
McEvoy, J. P., Freudenreich, O., & Wilson, W. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00377-1 · Cited by 172
Wilk, C. M., Gold, J. M., Bartko, J. J., Dickerson, F., Fenton, W. S., Knable, M., Randolph, C., & Buchanan, R. W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.838 · Cited by 164
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
Koike, K., Hashimoto, K., Takai, N., Shimizu, E., Komatsu, N., Watanabe, H., Nakazato, M., Okamura, N., Stevens, K. E., Freedman, R., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.016 · Cited by 127
Self-citationRiley, B. P., MAKOFF, A. J., Mogudi-Carter, M., Jenkins, T., Williamson, R., Collier, D. A., & Murray, R. M. (2000) · American Journal of Medical Genetics · Cited by 124
Simosky, J. K., Stevens, K. E., Adler, L. E., & Freedman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1285-x · Cited by 121
Self-citationWoodruff‐Pak, D. S., Li, Y.-T., & Kem, W. R. (1994) · Brain Research · doi:10.1016/0006-8993(94)91665-9 · Cited by 119
Self-citationKem, W. R., Mahnir, V. M., Prókai, L., Papke, R. L., Cao, X., LeFrancois, S., Wildeboer, K. M., Prókai-Tátrai, K., Porter-Papke, J., & Soti, F. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.56 · Cited by 100
Self-citationChung, Y., Li, Z., Dai, J., Meltzer, H. Y., & Ichikawa, J. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.009 · Cited by 93
Human α 7 nicotinic acetylcholine receptor responses to novel ligands
Briggs, C. A., McKenna, D. G., & Piattina-kaplan, M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00028-5 · Cited by 88
Nicotine improves delayed recognition in schizophrenic patients
Myers, C. S., Robles, O., Kakoyannis, A. N., Sherr, J. D., Avila, M. T., Blaxton, T. A., & Thaker, G. K. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1764-8 · Cited by 87
Schizophrenia and smoking: Evidence for a common neurobiological basis?
Stassen, H. H., Bridler, R., H�gele, S., Hergersberg, M., Mehmann, B., Schinzel, A., Weisbrod, M., & Scharfetter, C. (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000403)96:2<173::aid-ajmg10>3.0.co;2-u · Cited by 86
Xu, J., Pato, M. T., Torre, C. D., Medeiros, H., Carvalho, C. B., Basile, V. S., Bauer, A., Dourado, A., Valente, J., Soares, M. J., et al. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1549 · Cited by 84
Liu, C., Hwu, H., Lin, M., Ouyang, W., Lee, S. F. ‐., Fann, C. S. J., Wong, S., & Hsieh, S.-H. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1547 · Cited by 83
Tsuang, D. W., Skol, A. D., Faraone, S. V., Bingham, S. F., Young, K. A., Prabhudesai, S., Haverstock, S. L., Mena, F., Menon, A. S., Bisset, D., et al. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1550 · Cited by 80
Houy, E., Raux, G., Thibaut, F., Belmont, A., Demily, C., Allio, G., Haouzir, S., Fouldrin, G., Petit, M., Frébourg, T., et al. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001443 · Cited by 67
Galantamine for Treatment-Resistant Schizophrenia
Allen, T. B., & McEvoy, J. P. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1244 · Cited by 58
The effect of state on sensory gating: comparison of waking, REM and non-REM sleep
Kisley, M. A., D, A. O. M., & Freedman, R. (2001) · Clinical Neurophysiology · doi:10.1016/s1388-2457(01)00578-8 · Cited by 57
Self-citationLinkage analysis of schizophrenia to chromosome 15
Gejman, P. V., Sanders, A. R., Badner, J. A., Cao, Q., & Zhang, J. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1552 · Cited by 55
The Structural Basis for GTS-21 Selectivity between Human and Rat Nicotinic α7 Receptors
Stokes, C. A., Papke, J. K. P., Horenstein, N. A., Kem, W. R., McCormack, T. J., & Papke, R. L. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.14 · Cited by 53
Self-citationPharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition
Mahnir, V. M., Lin, B., Prókai-Tátrai, K., & Kem, W. R. (1998) · Biopharmaceutics & Drug Disposition · Cited by 40
Self-citation
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system
Taly, A., Corringer, P.-J., Guedin, D., Lestage, P., & Changeux, J.-P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2927 · Cited by 703
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Self-citationThe alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation
de Jonge, W. J., & Ulloa, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707264 · Cited by 629
Metadata
- Authors
- Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., Stevens, J. O., Martin, L., Adler, L. E., Soti, F., Kem, W. R., & Freedman, R.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-06-01
- Volume
- 63
- Issue
- 6
- Pages
- 630
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2124533302
- Cited by
- 527
- References
- 44
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.